{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:40:09Z","timestamp":1785883209966,"version":"3.56.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93021C00014"],"award-info":[{"award-number":["75N93021C00014"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N39019C00051"],"award-info":[{"award-number":["75N39019C00051"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-66829-y","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T14:35:49Z","timestamp":1765636549000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Human monoclonal antibodies that target clade 2.3.4.4b H5N1 hemagglutinin"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9139-9915","authenticated-orcid":false,"given":"Garazi Pe\u00f1a","family":"Alzua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5926-8966","authenticated-orcid":false,"given":"Andr\u00e9 Nicol\u00e1s","family":"Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1907-0336","authenticated-orcid":false,"given":"Temima","family":"Yellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1564-3298","authenticated-orcid":false,"given":"Disha","family":"Bhavsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3751-8036","authenticated-orcid":false,"given":"Madhumathi","family":"Loganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"Bushfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J. M.","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alesandra J.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trushar","family":"Jeevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4397-7132","authenticated-orcid":false,"given":"Richard","family":"Webby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Marizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3402-2609","authenticated-orcid":false,"given":"Julianna","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7153-3769","authenticated-orcid":false,"given":"Andrew B.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Andrew","family":"Duty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4121-776X","authenticated-orcid":false,"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"key":"66829_CR1","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1637\/0005-2086-47.s3.832","volume":"47","author":"LD Sims","year":"2003","unstructured":"Sims, L. D. et al. Avian influenza in Hong Kong 1997-2002. Avian Dis. 47, 832\u2013838 (2003).","journal-title":"Avian Dis."},{"key":"66829_CR2","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/infdis\/jiae379","volume":"230","author":"RJ Webby","year":"2024","unstructured":"Webby, R. J. & Uyeki, T. M. An update on highly pathogenic avian influenza A(H5N1) virus, clade 2.3.4.4b. J. Infect. Dis. 230, 533\u2013542 (2024).","journal-title":"J. Infect. Dis."},{"key":"66829_CR3","unstructured":"Confirmations of highly pathogenic avian influenza in commercial and backyard flocks., https:\/\/www.aphis.usda.gov\/livestock-poultry-disease\/avian\/avian-influenza\/hpai-detections\/commercial-backyard-flocks (2024)."},{"key":"66829_CR4","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3201\/eid3003.231098","volume":"30","author":"PI Plaza","year":"2024","unstructured":"Plaza, P. I., Gamarra-Toledo, V., Eugui, J. R. & Lambertucci, S. A. Recent changes in patterns of mammal infection with highly pathogenic avian influenza A(H5N1) virus worldwide. Emerg. Infect. Dis. 30, 444\u2013452 (2024).","journal-title":"Emerg. Infect. Dis."},{"key":"66829_CR5","unstructured":"Federal and State Veterinary Agencies Share Update on HPAI Detections in Oregon Backyard Farm, Including First H5N1 Detections in Swine, https:\/\/www.aphis.usda.gov\/news\/agency-announcements\/federal-state-veterinary-agencies-share-update-hpai-detections-oregon (2024)."},{"key":"66829_CR6","unstructured":"CDC A(H5N1) Bird Flu Response Update November 18, 2024, https:\/\/www.cdc.gov\/bird-flu\/spotlights\/h5n1-response-11152024.html (2024)."},{"key":"66829_CR7","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1086\/656316","volume":"202","author":"W Adisasmito","year":"2010","unstructured":"Adisasmito, W. et al. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry. J. Infect. Dis. 202, 1154\u20131160 (2010).","journal-title":"J. Infect. Dis."},{"key":"66829_CR8","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1021\/acs.biochem.5c00192","volume":"64","author":"S Subramaniam","year":"2025","unstructured":"Subramaniam, S., Saville, J. W., Feng, F. & Freiburger, L. Therapeutic antibodies for infectious diseases: recent past, present, and future. Biochemistry 64, 3487\u20133494 (2025).","journal-title":"Biochemistry"},{"key":"66829_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-med-061323-073837","volume":"76","author":"A Casadevall","year":"2025","unstructured":"Casadevall, A. & Focosi, D. Lessons from the use of monoclonal antibodies to SARS-CoV-2 spike protein during the COVID-19 pandemic. Annu Rev. Med 76, 1\u201312 (2025).","journal-title":"Annu Rev. Med"},{"key":"66829_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2576","volume":"34","author":"ATK Sevendal","year":"2024","unstructured":"Sevendal, A. T. K., Hurley, S., Bartlett, A. W., Rawlinson, W. & Walker, G. J. Systematic review of the efficacy and safety of RSV-specific monoclonal antibodies and antivirals in development. Rev. Med Virol. 34, e2576 (2024).","journal-title":"Rev. Med Virol."},{"key":"66829_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2023.101339","volume":"61","author":"P Rijal","year":"2023","unstructured":"Rijal, P. & Donnellan, F. R. A review of broadly protective monoclonal antibodies to treat Ebola virus disease. Curr. Opin. Virol. 61, 101339 (2023).","journal-title":"Curr. Opin. Virol."},{"key":"66829_CR12","doi-asserted-by":"publisher","first-page":"17957","DOI":"10.1073\/pnas.1906613117","volume":"117","author":"AH Ellebedy","year":"2020","unstructured":"Ellebedy, A. H. et al. Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humans. Proc. Natl. Acad. Sci. USA 117, 17957\u201317964 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"66829_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16256-y","volume":"11","author":"C Wang","year":"2020","unstructured":"Wang, C. et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat. Commun. 11, 2251 (2020).","journal-title":"Nat. Commun."},{"key":"66829_CR14","doi-asserted-by":"publisher","first-page":"e311","DOI":"10.1016\/S1473-3099(22)00311-5","volume":"22","author":"D Focosi","year":"2022","unstructured":"Focosi, D. et al. Monoclonal antibody therapies against SARS-CoV-2. Lancet Infect. Dis. 22, e311\u2013e326 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"66829_CR15","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/22221751.2019.1597644","volume":"8","author":"I Widjaja","year":"2019","unstructured":"Widjaja, I. et al. Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein. Emerg. Microbes Infect. 8, 516\u2013530 (2019).","journal-title":"Emerg. Microbes Infect."},{"key":"66829_CR16","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00626-24","volume":"98","author":"PS Meade","year":"2024","unstructured":"Meade, P. S. et al. Detection of clade 2.3.4.4b highly pathogenic H5N1 influenza virus in New York City. J. Virol. 98, e0062624 (2024).","journal-title":"J. Virol."},{"key":"66829_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35586-7","volume":"13","author":"D Stadlbauer","year":"2022","unstructured":"Stadlbauer, D. et al. Antibodies targeting the neuraminidase active site inhibit influenza H3N2 viruses with an S245N glycosylation site. Nat. Commun. 13, 7864 (2022).","journal-title":"Nat. Commun."},{"key":"66829_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114922","volume":"43","author":"JJ Clark","year":"2024","unstructured":"Clark, J. J. et al. Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination. Cell Rep. 43, 114922 (2024).","journal-title":"Cell Rep."},{"key":"66829_CR19","unstructured":"Assessment of risk associated with recent influenza A(H5N1) clade 2.3.4.4b viruses https:\/\/cdn.who.int\/media\/docs\/default-source\/influenza\/avian-and-other-zoonotic-influenza\/h5-risk-assessment-dec-2022.pdf (2022)."},{"key":"66829_CR20","unstructured":"CDC Confirms First Severe Case of H5N1 Bird Flu in the United States, https:\/\/www.cdc.gov\/media\/releases\/2024\/m1218-h5n1-flu.html (2024)."},{"key":"66829_CR21","doi-asserted-by":"publisher","unstructured":"Jassem, A. N. et al. Critical Illness in an Adolescent with Influenza A(H5N1) Virus Infection. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMc2415890 (2024).","DOI":"10.1056\/NEJMc2415890"},{"key":"66829_CR22","doi-asserted-by":"publisher","unstructured":"Castillo, A. et al. The first case of human infection with H5N1 avian Influenza A virus in Chile. J. Travel Med. 30, https:\/\/doi.org\/10.1093\/jtm\/taad083 (2023).","DOI":"10.1093\/jtm\/taad083"},{"key":"66829_CR23","doi-asserted-by":"publisher","unstructured":"Bruno, A. et al. First case of human infection with highly pathogenic H5 avian Influenza A virus in South America: A new zoonotic pandemic threat for 2023? J. Travel Med. 30, https:\/\/doi.org\/10.1093\/jtm\/taad032 (2023).","DOI":"10.1093\/jtm\/taad032"},{"key":"66829_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3201\/eid1201.051254","volume":"12","author":"ED Kilbourne","year":"2006","unstructured":"Kilbourne, E. D. Influenza pandemics of the 20th century. Emerg. Infect. Dis. 12, 9\u201314 (2006).","journal-title":"Emerg. Infect. Dis."},{"key":"66829_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2024.105959","volume":"229","author":"K Andreev","year":"2024","unstructured":"Andreev, K. et al. Genotypic and phenotypic susceptibility of emerging avian influenza A viruses to neuraminidase and cap-dependent endonuclease inhibitors. Antivir. Res. 229, 105959 (2024).","journal-title":"Antivir. Res."},{"key":"66829_CR26","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41586-024-08254-7","volume":"636","author":"C Gu","year":"2024","unstructured":"Gu, C. et al. A human isolate of bovine H5N1 is transmissible and lethal in animal models. Nature 636, 711\u2013718 (2024).","journal-title":"Nature"},{"key":"66829_CR27","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1093\/cid\/ciae368","volume":"79","author":"SK Tan","year":"2024","unstructured":"Tan, S. K. et al. A randomized, placebo-controlled trial to evaluate the safety and efficacy of VIR-2482 in healthy adults for prevention of influenza A illness (PENINSULA). Clin. Infect. Dis. 79, 1054\u20131061 (2024).","journal-title":"Clin. Infect. Dis."},{"key":"66829_CR28","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1126\/science.aay0678","volume":"366","author":"D Stadlbauer","year":"2019","unstructured":"Stadlbauer, D. et al. Broadly protective human antibodies that target the active site of influenza virus neuraminidase. Science 366, 499\u2013504 (2019).","journal-title":"Science"},{"key":"66829_CR29","doi-asserted-by":"publisher","unstructured":"Margine, I., Palese, P. & Krammer, F. Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. J. Vis. Exp. e51112 https:\/\/doi.org\/10.3791\/51112 (2013).","DOI":"10.3791\/51112"},{"key":"66829_CR30","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/22221751.2018.1564369","volume":"8","author":"F Amanat","year":"2019","unstructured":"Amanat, F., Meade, P., Strohmeier, S. & Krammer, F. Cross-reactive antibodies binding to H4 hemagglutinin protect against a lethal H4N6 influenza virus challenge in the mouse model. Emerg. Microbes Infect. 8, 155\u2013168 (2019).","journal-title":"Emerg. Microbes Infect."},{"key":"66829_CR31","doi-asserted-by":"crossref","unstructured":"Duty, J. A. et al. Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants.\u00a0Med. 3, 705\u2013721.e11 (2022).","DOI":"10.1016\/j.medj.2022.08.002"},{"key":"66829_CR32","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1126\/science.1222908","volume":"337","author":"C Dreyfus","year":"2012","unstructured":"Dreyfus, C. et al. Highly conserved protective epitopes on influenza B viruses. Science 337, 1343\u20131348 (2012).","journal-title":"Science"},{"key":"66829_CR33","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/ni.3684","volume":"18","author":"R Nachbagauer","year":"2017","unstructured":"Nachbagauer, R. et al. Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins. Nat. Immunol. 18, 464\u2013473 (2017).","journal-title":"Nat. Immunol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66829-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66829-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66829-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T04:40:41Z","timestamp":1767760841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66829-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["66829"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-66829-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,13]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Icahn School of Medicine at Mount Sinai has filed patent applications regarding the described H5 mAbs which list G.P.A., J.A.D. and F.K. as inventors. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays, NDV-based SARS-CoV-2 vaccines influenza virus vaccines and influenza virus therapeutics which list F.K. as co-inventor and F.K. has received royalty payments from some of these patents. Mount Sinai has spun out a company, Castlevax, to develop SARS-CoV-2 vaccines. F.K. is co-founder and scientific advisory board member of Castlevax. F.K. has consulted for Merck, GSK, Sanofi, Curevac,\u00a0Gritstone, Seqirus and Pfizer and is currently consulting for 3rd Rock Ventures and Avimex. The Krammer laboratory is also collaborating with Dynavax on influenza vaccine development. ABW has received royalty payments for the licensure of a prefusion coronavirus spike stabilization technology for which he is a co-inventor. A.B.W. is currently consulting for Third Rock Ventures and Merida Biosciences. J.H. and A.B.W. are consultants for Third Rock Ventures. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"135"}}